🇺🇸 FDA
Patent

US 9822365

Compositions and methods for inhibiting expression of the PCSK9 gene

granted A61KA61K31/713A61P

Quick answer

US patent 9822365 (Compositions and methods for inhibiting expression of the PCSK9 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/713, A61P, A61P3/06, A61P43/00